Lonza received Swissmedic approval to operate a new aseptic drug‑product filling line in Stein, Switzerland, designed for highly potent biologics including ADCs. The GMP license upgrades Lonza’s capacity for liquid and lyophilized vial filling and adds advanced containment isolator technology aligned with Annex 1 sterile product requirements. The expansion strengthens Lonza’s integrated drug‑substance-to‑drug‑product offering and addresses a critical bottleneck in commercializing potent modalities that require specialized containment and handling. Sponsors facing long CDMO lead times now gain additional high‑containment capacity for clinical and potential commercial supply.